Intervention
Serplulimab
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 22 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
22 shownA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerNCT07739758 · 2026-08-18
RECRUITINGSerplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%NCT07596121 · 2026-05-13
RECRUITINGStudy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerNCT07231445 · 2026-04-21
RECRUITINGNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)NCT07283692 · 2026-03-01
RECRUITINGA Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNCT07269782 · 2026-01-20
RECRUITINGSerplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerNCT06860529 · 2025-04-15
RECRUITINGA Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsNCT06848699 · 2025-02-25
RECRUITINGNabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.NCT06781281 · 2024-12-04
RECRUITINGMaintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCNCT06497530 · 2024-12-01
RECRUITINGSerplulimab Combined With CCRT for LS-SCLC.NCT06295926 · 2024-04-04
RECRUITINGInduction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerNCT05766800 · 2023-03-14
RECRUITINGSerplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNCT07466303 · 2026-03-25
NOT_YET_RECRUITINGA Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerNCT07318883 · 2026-03-01
NOT_YET_RECRUITINGAn Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNCT07141771 · 2025-12-31
NOT_YET_RECRUITINGSerplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung CancerNCT07064876 · 2025-10-01
NOT_YET_RECRUITINGCryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung CancerNCT06580665 · 2024-09-01
NOT_YET_RECRUITINGEfficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLCNCT06364046 · 2024-04-01
UNKNOWNSerplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.NCT06195683 · 2023-12-01
UNKNOWNTesting the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLCNCT06350162 · 2023-10-18
UNKNOWNA Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsNCT05787613 · 2023-07-10
ACTIVE_NOT_RECRUITINGSafety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After TreatmentNCT05957510 · 2023-07-07
ACTIVE_NOT_RECRUITINGSerplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureNCT06334757 · 2023-05-08
UNKNOWNCommon conditions
Non-small Cell Lung Cancer3Small Cell Lung Cancer3Non Small Cell Lung Cancer2SCLC, Extensive Stage2Breast Cancer1Breast Cancer Invasive1Carcinoma1Early Lung Cancer1Extensive Stage Lung Small Cell Cancer1Extensive-Stage Small Cell Lung Cancer1HR+/HER2- Breast Cancer1Locally Advanced1Non-Squamous Non-Small Cell Lung Cancer1NSCLC (Non-small Cell Lung Cancer)1NSCLC Stage IV1PDL1 Gene Mutation1Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer1Small-cell Lung Cancer1Solid Tumor Cancer1Squamous NSCLC1Triple Negative Breast Cancer1
Leading sponsors
Shanghai Henlius Biotech
4
Henan Cancer Hospital
3
Zhejiang Cancer Hospital
2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
1
Guangdong Association of Clinical Trials
1
Guangzhou Institute of Respiratory Disease
1
MediLink Therapeutics (Suzhou) Co., Ltd.
1
Peking Union Medical College Hospital
1
RenJi Hospital
1
Shanghai Chest Hospital
1
Shanghai Pulmonary Hospital, Shanghai, China
1
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
1
Tang-Du Hospital
1
The Central Hospital of Lishui City
1
Xi Junjie
1
Trial status mix
RECRUITING11
NOT_YET_RECRUITING5
UNKNOWN4
ACTIVE_NOT_RECRUITING2
Phase mix
PHASE217
PHASE13
NA2
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.